Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of the safety and feasibility of blinatumomab plus donor lymphocyte infusion to treat measurable residual disease-positive pediatric relapsed or refractory acute lymphoblastic leukemia after Hematopoietic Stem Cell Transplantation

Next Previous
X
Search
Trial Profile

Assessment of the safety and feasibility of blinatumomab plus donor lymphocyte infusion to treat measurable residual disease-positive pediatric relapsed or refractory acute lymphoblastic leukemia after Hematopoietic Stem Cell Transplantation

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Aug 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Antineoplastics; Inotuzumab ozogamicin
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 14 Aug 2022 New trial record
    • 17 Jun 2022 Results of an analysis of experience of three patients with post-transplant MRD-positive ALL who received blinatumomab and DLI presented at the 27th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top